PL377357A1 - Sposób i kompozycja do leczenia lęku - Google Patents

Sposób i kompozycja do leczenia lęku

Info

Publication number
PL377357A1
PL377357A1 PL377357A PL37735703A PL377357A1 PL 377357 A1 PL377357 A1 PL 377357A1 PL 377357 A PL377357 A PL 377357A PL 37735703 A PL37735703 A PL 37735703A PL 377357 A1 PL377357 A1 PL 377357A1
Authority
PL
Poland
Prior art keywords
compositions
treating anxiety
anxiety
treating
Prior art date
Application number
PL377357A
Other languages
English (en)
Inventor
Janet Codd
Bernard Beer
Original Assignee
Nascime Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nascime Limited filed Critical Nascime Limited
Publication of PL377357A1 publication Critical patent/PL377357A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
PL377357A 2002-12-04 2003-11-25 Sposób i kompozycja do leczenia lęku PL377357A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43074002P 2002-12-04 2002-12-04

Publications (1)

Publication Number Publication Date
PL377357A1 true PL377357A1 (pl) 2006-02-06

Family

ID=32469522

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377357A PL377357A1 (pl) 2002-12-04 2003-11-25 Sposób i kompozycja do leczenia lęku

Country Status (12)

Country Link
US (1) US20040192706A1 (pl)
EP (1) EP1581230A2 (pl)
JP (1) JP2006509789A (pl)
KR (1) KR20050085386A (pl)
CN (1) CN1720048A (pl)
AU (1) AU2003297559A1 (pl)
BR (1) BR0316192A (pl)
CA (1) CA2507609A1 (pl)
NO (1) NO20053310L (pl)
PL (1) PL377357A1 (pl)
RU (1) RU2005120749A (pl)
WO (1) WO2004050019A2 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155170A2 (en) * 2007-06-08 2010-02-24 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626538A (en) * 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
US4521422A (en) * 1983-06-23 1985-06-04 American Cyanamid Company Aryl and heteroaryl[7-(aryl and heteroaryl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones
US6399621B1 (en) * 1999-08-10 2002-06-04 American Cyanamid Company N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration

Also Published As

Publication number Publication date
EP1581230A2 (en) 2005-10-05
NO20053310D0 (no) 2005-07-04
BR0316192A (pt) 2005-10-11
JP2006509789A (ja) 2006-03-23
CN1720048A (zh) 2006-01-11
NO20053310L (no) 2005-08-29
WO2004050019A2 (en) 2004-06-17
WO2004050019A9 (en) 2012-03-22
AU2003297559A1 (en) 2004-06-23
US20040192706A1 (en) 2004-09-30
KR20050085386A (ko) 2005-08-29
RU2005120749A (ru) 2006-01-20
WO2004050019A3 (en) 2004-08-12
CA2507609A1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
IL208191A0 (en) Compositions and methods for treating rage-associated disorders
IL164000A0 (en) Compositions and methods for treating emphysema
IL162696A0 (en) Apparatus and method for endoscopiccolectomy
IL176259A0 (en) Compositions and methods for treating diabetes
GB2421434B (en) Compositions And Methods For Treating Gynaecological Disorders
GB0519316D0 (en) "Method and apparatus"
EP1553960A4 (en) NEUREGULIN-BASED METHOD AND COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
IL164352A0 (en) Methods for treating tweak-related conditions
IL164219A0 (en) Method for treating and preventing hyparathyroidism
GB0609689D0 (en) Non-nucleotide compositions and method for treating pain
EP1578197A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF LUPUS NEPHRITIS
AU2003297573A8 (en) Compositions and methods for treating transplants
AU2003232044A8 (en) Composition and method for dermatological treatment
EP1684771A4 (en) COMPOSITION AND METHOD
ZA200602144B (en) A composition and method of treatment for urogenital conditions
ZA200602275B (en) Composition and method for treating bezoar and trichobezoar
ZA200610474B (en) Compositions and methods for treating inflammatory disorders
AU2003295574A8 (en) Method and compositions for temporarily incapaciting subjets
PL376932A1 (pl) Sposób traktowania żużla
AU2003267241A1 (en) Method for treating depression and/or anxiety
AU2002364679A8 (en) Method and compositions for treating respiratory pathologies
EP1594473A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF AGE-RELATED DISEASES
AU2003275433A8 (en) Compositions and methods for treating pain
PL377357A1 (pl) Sposób i kompozycja do leczenia lęku
IL163878A0 (en) Compositions and methods for treating mdma-inducedtoxicity

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)